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Loss of PBRM1 rescues VHL dependent replication
stress to promote renal carcinogenesis
Judit Espana-Agusti1,6, Anne Warren2, Su Kit Chew3,4, David J. Adams5 & Athena Matakidou 1,7
Inactivation of the VHL (Von Hippel Lindau) tumour suppressor has long been recognised as
necessary for the pathogenesis of clear cell renal cancer (ccRCC); however, the molecular
mechanisms underlying transformation and the requirement for additional genetic hits
remain unclear. Here, we show that loss of VHL alone results in DNA replication stress and
damage accumulation, effects that constrain cellular growth and transformation. By contrast,
concomitant loss of the chromatin remodelling factor PBRM1 (mutated in 40% of ccRCC)
rescues VHL-induced replication stress, maintaining cellular ﬁtness and allowing proliferation.
In line with these data we demonstrate that combined deletion of Vhl and Pbrm1 in the mouse
kidney is sufﬁcient for the development of fully-penetrant, multifocal carcinomas, closely
mimicking human ccRCC. Our results illustrate how VHL and PBRM1 co-operate to drive renal
transformation and uncover replication stress as an underlying vulnerability of all VHL
mutated renal cancers that could be therapeutically exploited.
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Renal cancer is the twelfth commonest cancer worldwide,accounting for 338,000 new cases and 143,000 cancer-related deaths a year1. Around 50% of all patients develop
metastatic disease and in this setting, renal cancer remains
incurable with a median survival of around 28 months2. The
development of effective treatment regimens has been hampered
by a limited understanding of the basic molecular pathways
underpinning renal cell carcinoma (RCC) carcinogenesis and the
lack of genetically relevant animal models.
Clear cell RCC (ccRCC), the commonest histological subtype,
is characterised by the inactivation of VHL tumour suppressor
gene3. VHL is responsible for the ccRCC-predisposing syndrome,
von Hippel-Lindau4 and is inactivated by either mutation or
methylation in over 80% of sporadic cases5–7. The second allele is
lost as a part of large 3p deletions, observed in ~90% of all cases8–
10. Chromosome 3p loss and VHL mutation or methylation, are
early, truncal events during RCC development11 and therefore
considered crucial for renal transformation.
VHL is implicated in a number of cellular functions, disruption
of any or all of which could contribute to carcinogenesis. These
include mediation of adaptive responses to hypoxia (through
activation of hypoxia inducible factors HIF1a and HIF2a),
extracellular matrix assembly, ciliogenesis, microtubule stabilisa-
tion, senescence, and DNA repair3, 12. Current data, however,
suggest that VHL loss alone, though necessary, is not sufﬁcient for
tumour initiation in the kidney. First, kidneys of patients with
familial VHL disease typically contain many thousands of sites of
biallelic VHL loss, with ccRCC arising relatively infrequently13.
Second, large-scale sequencing efforts have shown that biallelic
intragenic VHL mutations are not observed in sporadic ccRCC
but instead one copy of the gene is always lost as a part of
chromosome 3p deletion, simultaneously affecting a number of
other genes11, 14. Third, deletion of Vhl or activation of its main
downstream effectors (Hif1a/Hif2a) within the mouse kidney
does not lead to tumour development15–19. These observations
suggest the requirement of additional genetic events to drive
transformation.
Recently, next-generation sequencing studies have identiﬁed
the SWI/SNF chromatin remodeller PBRM1 as the second most
frequently mutated ccRCC gene10, 14. Concomitant loss of VHL
and PBRM1 is observed in up to 40% of all cases14 and phylo-
genetic analyses have suggested that PBRM1 may act as a renal
cancer driver as mutations are frequently acquired early11. Here
we set out to ascertain the molecular interactions between VHL
and PBRM1, and their potential to drive renal carcinogenesis
in vivo. Our data show that loss of VHL alone induces replication
stress and DNA damage accumulation, responses that curtail
cellular proliferation and transformation. Signiﬁcantly, the con-
comitant loss of PBRM1 rescues VHL-dependent replication
stress, conferring a survival and proliferative advantage and
thereby permitting renal carcinogenesis. Our study provides
essential insights into the molecular mechanisms underpinning
renal transformation and highlights replication stress as an
underlying vulnerability of ccRCC.
Results
PBRM1 loss rescues VHL-induced replication stress. To iden-
tify interactions arising from the concurrent loss of VHL and
PBRM1 within the context of normal cellular physiology, we
generated primary mouse embryonic ﬁbroblasts (MEFs) from
either wild-type (WT), Vhlﬂ/ﬂ, Pbrm1ﬂ/ﬂ or double-mutant (Vhlﬂ/
ﬂ;Pbrm1ﬂ/ﬂ) conditional mice. Recombined MEFs are hereafter
referred to as Vhl−/−, Pbrm1−/− and Vhl−/−;Pbrm1−/− (Supple-
mentary Fig. 1a,b). To replicate physiological tissue conditions20
and avoid the well-documented sensitivity of MEFs to 21%
oxygen21, 22, all experiments were performed at 5% O2. As both
VHL and PBRM1 have been previously implicated in DNA repair
and the maintenance of genome stability12, 23–25, pathways
essential for tumour suppression, we decided to investigate their
combined effect on these processes.
Analysis of DNA damage markers demonstrated signiﬁcant
accumulation of γH2AX and 53BP1 foci in late (day 20 of culture)
vs. early (day 8) Vhl−/− cells (Fig. 1a and Supplementary Fig. 1c),
indicating accrual of DNA damage upon replication. Surprisingly,
this phenotype was restricted to Vhl−/− cells with Vhl−/−;Pbrm1
−/− MEFs displaying no signiﬁcant damage accumulation. This
disparity was not attributable to differences in the proliferation or
senescence rates between the two groups (Supplementary Fig. 1d,
e), suggesting that the rescue of this Vhl-induced phenotype was
mediated by loss of Pbrm1.
The accumulation of DNA damage markers in Vhl-deleted
cells is indicative of the presence of replication stress. Replication
stress broadly deﬁnes impediments in DNA replication, including
stalling and collapse of replication forks and activation of the
DNA damage response primarily mediated by the kinase ATR
(ATM- and Rad3-related)26. Indeed, late passage Vhl−/− MEFs
displayed signiﬁcant activation of both ATR and its effector
kinase CHK1 (Fig. 1a and Supplementary Fig. 1c). To investigate
whether VHL loss induces replication stress, MEFs were assayed
for hypersensitivity to mitomycin C (MMC) and aphidicolin
(APH), agents which result in replication fork stalling. Vhl−/−
cells displayed signiﬁcantly higher levels of DNA damage markers
upon treatment with these agents compared to non-recombined
controls (Fig. 1b and Supplementary Fig. 2). This phenotype was
rescued by concomitant treatment with cyclin-dependent kinase
inhibitors to halt S-phase progression (Fig. 1c), suggesting the
presence of a replication-dependent defect.
To ascertain the relevance of these observations within
differentiated renal tubular epithelia (the presumed cell of origin
of human ccRCC)27–29, we sought to generate genetically
engineered mice with renal tubular speciﬁc deletion of Vhl,
Pbrm1 or both Vhl and Pbrm1. We have previously described the
development of Pax8CreERT2 transgenic mice16 that allow highly
speciﬁc and inducible targeting of all renal tubular compartments
(proximal, distal tubules and collecting ducts). Pax8CreERT2
transgenic mice were crossed with Vhlﬂ/ﬂ, Pbrm1ﬂ/ﬂ and Vhlﬂ/ﬂ;
Pbrm1ﬂ/ﬂ conditional animals to generate compound mutants.
Tamoxifen administration induced deletion of target genes to
generate experimental (Vhl−/−, Pbrm1−/− and Vhl−/−;Pbrm1−/−)
and control (Vhlﬂ/ﬂ, Pbrm1ﬂ/ﬂ and Vhlﬂ/ﬂ;Pbrm1ﬂ/ﬂ) animals
(Supplementary Fig. 3a,b). Mice were treated with MMC and
their kidneys were assayed for markers of DNA damage. Post
MMC treatment, kidneys from Vhl−/− animals demonstrated a
threefold increase in the number of damaged tubular epithelia
and induction of cell cycle arrest (Fig. 1d and Supplementary
Fig 3c). Within individual animals, the extent of observed DNA
damage closely correlated with the degree of VHL deletion, as
assayed by CA9 positivity (Supplementary Fig. 3d). Signiﬁcantly,
Vhl−/−;Pbrm1−/− mice did not display hypersensitivity to MMC
nor γH2AX/CA9 correlation, despite displaying an equivalent
extent of VHL loss to Vhl−/− cohorts (Supplementary Fig. 3d).
Altogether, these data show that, both in vitro and in vivo, loss of
VHL induces replication stress that is rescued upon concomitant
loss of PBRM1.
Vhl loss induces replication fork instability and collapse. To
directly explore the effect of Vhl inactivation on DNA replication,
we evaluated replication fork dynamics using DNA ﬁbre assays.
Under unperturbed conditions, we observed no differences in
replication fork progression and sister fork symmetry (Fig. 2a and
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Supplementary Fig. 4a). However, upon treatment with aphidico-
lin, Vhl−/− MEFs showed impaired fork progression and evidence
of sister fork asymmetry consistent with fork stalling (Fig. 2b and
Supplementary Fig. 4b), implicating VHL in the maintenance of
DNA synthesis under conditions of replicative stress.
Following on from these observations we sought to determine
how the loss of VHL may impact on DNA replication. The best
studied function of VHL is its role in cellular oxygen sensing3.
Loss of VHL results in activation of cellular responses to hypoxia
despite normal oxygen conditions. Hypoxia has been implicated
in replication stress and the potentiation of genomic instability
through transcriptional and/or translational down regulation of
DNA repair pathways30–32. We, therefore, hypothesised that the
pseudohypoxia induced by VHL loss might have a similar effect.
Indeed, VHL depleted MEFs showed a signiﬁcant reduction in the
levels of RAD51 and replication protein A (RPA32), two essential
regulators of the replication stress response33, 34 (Fig. 2c and
Supplementary Fig. 4c). We observed no change in RAD51 and
RPA32 transcript levels suggesting that transcriptional repression
does not signiﬁcantly account for the observed depletion of
RAD51 and RPA upon loss of VHL (Supplementary Fig. 4d). As
both RAD51 and RPA have essential roles in preventing the
degradation of stalled forks and ensuring protection of nascent
DNA35, 36 we used DNA ﬁbre assays to investigate fork stability
in the context of Vhl deletion. Nascent replication tracts were IdU
and CIdU-labelled before treatment with aphidicolin and
replication fork stalling. Label retention (CIdU:IdU ratio) was
assessed as a measure of fork stability. Vhl−/− MEFs displayed a
signiﬁcant reduction of median CIdU:IdU tract ratios (Fig. 2d
and Supplementary Fig. 4e), indicating that VHL loss induces
fork instability and collapse, an effect consistent with the
observed depletion of RAD51 and RPA cellular pools.
PBRM1 loss induces H3K9me3-marked chromatin reorgani-
sation. Though RAD51 and RPA remain signiﬁcantly reduced in
double-mutant cells, these cells display no replication fork defects
(Fig. 2b, d). Furthermore, we did not observe any signiﬁcant
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Fig. 1 Loss of VHL induces replication stress rescued by concomitant loss of PBRM1. a Representative photos of immunoﬂuorescence staining in day 20
recombined MEFs. b, c Quantiﬁcation of γH2AX foci formation following treatment of MEFs as indicated (b, n (independent experiments)= 3; c, left, n
(independent experiments)= 6; right, n (independent experiments)= 4). d Schematic of experimental design of in vivo Mitomycin C (MMC) experiment;
renal γH2AX quantiﬁcation following MMC and representative immunohistochemical photos (n (mice); Saline: control= 6; MMC: control= 16; Vhl−/−= 6;
Pbrm1−/−= 3; Vhl−/−;Pbrm1−/−= 7). TAM: tamoxifen. Scale bars, 100 μm. b, c Graphs depict means± s.e.m. (error bars); two-way ANOVA, Sidak’s
correction. d, Graph depicts means± s.d. (error bars); Kruskall–Wallis, Dunn’s correction. ***p< 0.001, **p< 0.01, *p< 0.05
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differences in the activation of DNA damage responses in PBRM1
depleted cells (Supplementary Fig. 4f), suggesting that PBRM1
loss bypasses VHL-induced replication stress through an alter-
native pathway. PBRM1 encodes BAF180, a component of the
SWI/SNF chromatin–remodeller complex PBAF, capable of
modulating DNA/chromatin interactions37. Recent studies have
shown that the chromatin context in which replication stress
occurs can strongly inﬂuence DNA damage responses, with the
preferential enrichment of γH2AX in heterochromatic regions
marked by H3K9me331, 38, 39. Furthermore, the modulation of
chromatin structure and speciﬁcally H3K9me3 is able to modify
DNA replication, restore repair capacity and suppress DNA
damage38–40. We, therefore, ascertained the chromatin localisa-
tion of DNA damage observed following MMC in Vhl−/− MEFs
and found that γH2AX foci were preferentially associated with
H3K9me3-marked chromatin (Fig. 3a). We thus hypothesised
that PBRM1 loss could alleviate replication stress by modifying
chromatin structure.
We ﬁrst examined the distribution of nuclear H3K9me3 in
MEFs. Although we detected no change in the total levels of
cellular H3K9me3 between different genotypes, there was a
striking difference in its distribution, with Pbrm1−/− and Vhl−/−;
Pbrm1−/− MEFs displaying more diffuse staining patterns and a
signiﬁcant reduction in the number of distinct foci (Fig. 3b and
Supplementary Fig. 5a). Furthermore, examination of H3K9me3
in the kidneys of control, Vhl−/−, Pbrm1−/− and Vhl−/−;Pbrm1
−/− mice revealed a similar shift in distribution patterns, with an
overall reduction in the number of discernible foci in mice lacking
PBRM1 (Fig. 3c and Supplementary Fig. 5b). The effect of
PBRM1 loss on chromatin structure appeared to be speciﬁc to
H3K9me3 with no differences observed in other heterochromatin
markers (Supplementary Fig. 5c,d).
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Fig. 2 Loss of VHL induces replication fork stalling and collapse. a, b DNA ﬁbre analyses following the indicated treatments. Top: DNA ﬁbre assay
experimental design. Bottom left: Representative images of labelled replication tracts and dot plot of CIdU:IdU track ratio in MEFs of indicated genotype
(data from representative experiment; n> 85 tracts analysed for each genotype per experiment, n (independent experiments)= 3). Bottom right:
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To ascertain whether H3K9me3 modulation is able to rescue
VHL-dependent replication stress, Vhl−/− MEFs were treated
with the histone lysine methyltransferase inhibitor chaetocin41 at
doses sufﬁcient to reduce the number of distinct H3K9me3
nuclear foci without depleting modiﬁcation levels (to recapitulate
loss of PBRM1; Supplementary Fig. 5e–g). Treatment with
chaetocin was able to reverse the previously observed, VHL-
induced MMC and APH hypersensitivity (Fig. 3d) suggesting that
the rescue of VHL-induced replication stress by PBRM1 is
mediated at least in part by its effects on H3K9me3 organisation.
PBRM1 loss restores the cellular ﬁtness of VHL-deleted cells.
Replication stress and the ensuing DNA damage induce check-
point activation and cell cycle arrest, thereby curtailing cellular
proliferation and cancer growth42. We therefore hypothesised
that loss of PBRM1 and subsequent rescue of the DNA damage
caused by VHL deletion will confer a cellular ﬁtness advantage to
these cells. Though primary Vhl−/− and Vhl−/−;Pbrm1−/− MEFs
showed no difference in their proliferation rates under unper-
turbed culture conditions, we observed a differential response
following treatment with MMC, with the reduced viability of Vhl
−/− cells but not the double mutants (Fig. 4a).
The inducible nature of our genetically modiﬁed mouse models
allows induction of genetic changes upon a deﬁned time point
(tamoxifen administration) thereby permitting observation and
fate determination of recombined cells over time. To assess in vivo
proliferative differences we quantiﬁed the allelic frequency of the
recombined Vhl allele (Vhl−) in young (<12 months) and aged
(>20 months) Vhl−/− and Vhl−/−;Pbrm1−/− mutant mice. Renal
Vhl− allelic content did not vary with age in Vhl−/− mice (Fig. 4b).
In contrast, Vhl−/−;Pbrm1−/− mice showed a 5-fold increase in Vhl
− allelic content with increasing age, indicating that double-mutant
epithelia gain a signiﬁcant proliferative advantage over Vhl-deleted
cells. The expansion of double-mutant epithelial cells was further
conﬁrmed by CA9 immunohistochemistry (a marker of VHL loss)
demonstrating a clear increase in the number of positively staining
double-mutant epithelia over time (Fig. 4c). No such change was
observed in Vhl-deleted animals.
These observations support our hypothesis that loss of PBRM1
improves the cellular ﬁtness of VHL-defective cells permitting
cellular growth and enhancing their proliferative capacity.
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Vhl−/−;Pbrm1−/− mice develop clear cell RCCs. To ascertain
whether biallelic deletion of Vhl and Pbrm1 is indeed sufﬁcient to
promote renal transformation, Vhl−/−, Pbrm1−/− and Vhl−/−;
Pbrm1−/−mice as well as control animals were aged and observed
for tumour development.
No renal tumours were observed in any of the aged control,
Vhl−/− or Pbrm1−/− animals. In contrast, 100% of Vhl−/−;Pbrm1
−/− mice developed renal cancers by 20 months of age (Fig. 5a
and Supplementary Fig. 6a). Double-mutant mice displayed a
spectrum of premalignant and malignant lesions ranging from
simple, benign cysts (with one to two cell layers of bland
epithelium), to atypical cysts (demonstrating epithelial hyperpla-
sia with or without mild cytological atypia) and multifocal
neoplastic tumours (Fig. 5b and Supplementary Fig. 6b).
Importantly, lesions arose within microscopically normal renal
cortical parenchyma as is commonly observed in the sporadic
cases of human ccRCC. No macroscopic metastases were
observed in any of the mice. All renal lesions displayed carbonic
anhydrase 9 (CA9) positivity, a diagnostic marker of human clear
cell RCC and VHL inactivation43. Vhl and Pbrm1 were conﬁrmed
to be homozygously deleted both by PCR and immunohisto-
chemical analysis of neoplastic lesions (Fig. 5c and Supplemen-
tary Fig. 6c), indicating that these arose from double-mutant
epithelia. The Vhl−/−;Pbrm1−/− tumours displayed solid growth
patterns with prominent vasculature and were composed of cells
with eosinophilic or clear cytoplasm, and increased proliferative
index, features reminiscent of the histopathological appearances
of human ccRCC (Fig. 5d, e and Supplementary Fig. 6d). Renal
tubular marker immunohistochemistry (megalin, Tamm–Horsfall
protein (THP) and aquaporin 2, for proximal, distal tubules and
collecting ducts, respectively) revealed all lesions staining strongly
positive for megalin but no other renal markers, suggesting they
originated from epithelia of proximal renal tubules
(Supplementary Fig. 6e). Altogether, these data indicate that the
combined loss of Vhl and Pbrm1 within mouse tubular epithelia
is sufﬁcient for the development of renal neoplasias closely
resembling the human disease.
Discussion
Here we report the generation of a novel genetically and clinically
relevant mouse model of sporadic renal cell carcinoma and
provide for the ﬁrst time mechanistic data shedding light into the
early events driving renal carcinogenesis and the essential tumour
suppressor role of PBRM1. Our data shows that loss of VHL
induces replication stress and DNA damage accumulation,
responses that curtail cellular proliferation and transformation.
Signiﬁcantly, we ﬁnd that loss of PBRM1, through modulation of
H3K9me3-marked heterochromatin, rescues VHL-dependent
replication stress and confers a survival and proliferative advan-
tage, thereby permitting renal carcinogenesis (Fig. 5f).
Replication stress is a complex phenomenon that has serious
implications for genome stability, cell survival and human dis-
ease. It has being increasingly recognised as a hallmark of pre-
cancerous and early neoplastic lesions that leads to genomic
instability and activation of DDR responses leading to apoptosis
or senescence, thereby curtailing their growth26. In ccRCC
replication stress has been observed in the absence of SETD2 and
is shown to enhance genomic instability and heterogeneity,
impacting on cancer progression44, 45. Our data now establish
replication stress as an early, underlying defect in the vast
majority of ccRCCs, driven by the loss of VHL and its effects on
replication fork progression and stability. Both the observed
depletion of cellular RAD51 and RPA levels, two proteins
essential for the protection and restart of replication forks33, 34, as
well as the induction of replication stress have been previously
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associated with conditions of hypoxia30, 31, suggesting that these
are likely to represent HIF-dependent responses. Importantly, our
results provide a biological explanation for the lack of transfor-
mation upon loss of VHL alone and the need for additional
genetic hits to initiate renal carcinogenesis.
To overcome oncogene-induced replication stress and allow
tumour progression, a second, essential step in cancer develop-
ment involves suppression of the DDR responses, commonly
achieved through mutations targeting TP53, ATM or MDM2
genes26. Mutations of these genes though commonly observed in
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other tumour types are rare in ccRCC46. Our data shows that in
the case of ccRCC, rescue of the replication stress response can be
achieved through loss of the SWI/SNF chromatin remodeller
PBRM1 and appears to be mediated, at least in part, through
changes in H3K9me3-marked heterochromatin. H3K9me3 has
been previously shown to play a critical role in linking chromatin
structure to replication and the DDR response31, 40, 47. Further-
more, modulation of H3K9me3 can rescue the DNA repair
defects observed with ATM deﬁciency38 as well as the damage
accumulation and early senescence associated with progeria39.
The mechanisms underlying these observations are currently
unclear but are thought to involve modulation of DDR responses.
Therefore, one mechanism by which loss of heterochromatin
organisation (in the absence of PBRM1) could rescue the VHL-
induced replication defects is through alterations in DDR sig-
nalling. Though we see no evidence of a signiﬁcant defect in the
activation of DNA damage responses upon PBRM1 loss, further
detailed investigation in future studies is required to precisely
deﬁne the molecular interactions underlying these ﬁndings.
Whatever the precise mechanism of replication stress rescue, both
our in vitro and in vivo data clearly show that loss of PBRM1
restores the cellular ﬁtness and proliferative potential of Vhl-
deleted cells and is therefore critical for renal transformation.
SWI/SNF genes are commonly mutated across multiple cancer
types and recent studies have reported their role in controlling
chromatin structure and subsequent gene expression for the
suppression of tumour development48–50. Our ﬁndings identify
additional tumour suppressive functions mediated by SWI/SNF
genes beyond the control of gene expression and highlight the
interaction of chromatin structure and replication stress in
initiating carcinogenesis. As a number of histone modiﬁers have
been implicated in ccRCC development it will be of great interest
to establish their precise interactions with VHL loss and the
ensuing replication stress response.
Finally, we report the development of a novel genetically and
clinically relevant mouse model of ccRCC representative of the
sporadic form of the disease. While this manuscript was under
preparation two groups reported the generation of mice with
targeted disruption of Vhl and Pbrm1 in the kidney51, 52. Nar-
gund et al.51 induced Vhl and Pbrm1 deletion using a traditional
Ksp-Cre driver with mice developing renal hydronephrosis,
polycystic kidneys, renal failure and occasional renal tumours
(observed in 30% of mice). In the second study, Gu et al.52 uti-
lised the same promoter as used here (Pax8) to drive constitutive
expression of Cre recombinase from early kidney development,
with mice developing renal cancers of similar histological
appearances to the ones observed in our model. In contrast to
these studies, our use of Pax8-CreERT2 transgene allows for
temporal and spatial control of Vhl and Pbrm1 deletion and,
therefore, the speciﬁc targeting of fully developed renal tubular
epithelium. Thereby our study provides proof that ccRCC can
arise from the fully differentiated epithelium of renal proximal
tubules. Furthermore, the inducible nature of our model avoids
potential confounding by effects of Vhl and Pbrm1 deletion
during renal embryogenesis (as observed in the other RCC mouse
models). As a consequence, the tumours observed develop within
normal surrounding renal parenchyma and without signs of
morbidity, representing an accurate model of early, sporadic
human ccRCC and therefore a useful tool for the discovery and
preclinical evaluation of new methodologies for early detection,
prevention and treatment of the disease. Importantly, our study
provides essential insights into the molecular mechanisms
underpinning renal carcinogenesis, highlighting replication stress
as an underlying vulnerability for the majority of ccRCC and
providing opportunities for the development of much needed
novel therapeutics.
Methods
Data reporting. No statistical methods were used to predetermine sample size. The
experiments were not randomised and the investigators were not blinded to allo-
cation during experiments. For outcome assessment most experiments were
automatically analysed by Fiji scripts to minimise potential human bias. When
manual annotation was required, blinding precautions were made.
Mouse strains and treatments. Pax8CreERT2 transgenic mice have been pre-
viously described16. Conditional Vhlﬂ/ﬂ mice were obtained from Jackson
Laboratories (B6.129S4(C)-Vhltm1Jae/J)53. Pbrm1ﬂ/ﬂ mice were generated by the
Wellcome Trust Sanger Institute (Hinxton, UK), using European Conditional
Mouse Mutagenesis Program (EUCOMM) targeted embryonic stem cells
(Pbrm1tm1a(EUCOMM)Wtsi; clone ID EPD0089_3_C01). Brieﬂy, a knockout-ﬁrst
conditional allele composed of an IRES:lacZ trapping cassette and a ﬂoxed
promoter-driven neomycin cassette ﬂanking exon 4 of the Pbrm1 gene (Extended
Data Fig. 3a), was targeted in C57BL/6 N embryonic stem cells54. The
EPD0089_3_C01 clone was passaged twice in 2i/LIF media55 at low density to
enrich for ground state pluripotent cells. ES cell clones were isolated and expanded
for injection into 8-cell embryos to produce chimeric founders. Genotyped progeny
that were positive for germline transmission were bred, and ﬁrst generation off-
spring that inherited the targeted allele were subsequently mated with FLPeR
mice56 to remove the lacZ/neomycin selection cassette, leaving loxP sites on either
side of exon 4 (exon 2 of the translated transcript). The FLPeR allele was bred out
of the mouse line following cassette elimination. All mice were maintained on a
C57BL/6 background. Mice were crossbred to produce experimental cohorts
(Pax8CreERT2;Vhlﬂ/ﬂ, Pax8CreERT2;Pbrm1ﬂ/ﬂ and Pax8CreERT2;Vhlﬂ/ﬂ;Pbrm1ﬂ/ﬂ)
and littermate controls (Vhlﬂ/ﬂ, Pbrm1ﬂ/ﬂ and Vhlﬂ/ﬂ;Pbrm1ﬂ/ﬂ). Mouse genotypes
from ear biopsies were determined using real-time PCR with speciﬁc probes
designed for each gene (Transnetyx, Cordova, TN). To induce deletion of target
genes 4-week to 6-week-old experimental and control animals were injected
intraperitoneally with 2 mg of tamoxifen (Sigma, UK) for 5 consecutive days16.
For the mitomycin C (MMC) sensitivity studies, cohorts of mice 2–6 months
post tamoxifen induction (3–8 months of age) were treated with either saline or
MMC (0.5 mg/ml; Sigma, UK) at a single intraperitoneal injection of 5 mg/kg. Mice
were euthanized 10 days post treatment and kidneys were collected for further
analyses. Seven out of 39 (18%) animals showed macroscopic and microscopic
signs of renal cortical glomerular and tubular atrophy, a previously reported
toxicity of MMC in mice57. Affected mice were not of particular sex, age or
genotype (4/20 controls, 2/8 Pax8CreERT2;Vhlﬂ/ﬂ and 1/4 Pax8CreERT2;Pbrm1ﬂ/ﬂ)
and were excluded from further analysis.
Animal studies were conducted using age-matched littermate controls for each
experiment. Both male and female mice were used. Animals were maintained
under speciﬁc pathogen free conditions in accordance to Home Ofﬁce UK
regulations and the Animals (Scientiﬁc Procedures) Act, 1986. All experimental
protocols were approved by the Animal Welfare and Ethical Review Body
(AWERB) of the University of Cambridge CRUK Cambridge Institute.
Generation and culture of MEFs. MEFs were isolated from WT, Vhlﬂ/ﬂ, Pbrm1ﬂ/ﬂ
and Vhlﬂ/ﬂ;Pbrm1ﬂ/ﬂ animals at embryonic day 12.5 and aliquots were frozen at
passage 3. Cells were cultured in DMEM supplemented with 10% FBS (Thermo
Fisher) and 1% penicillin/streptomycin (Thermo Fisher) and maintained in con-
ventional cell culture incubators at 5% oxygen to replicate physiological tissue
conditions20. For Cre-mediated recombination of target genes, two days after
thawing, MEFs were treated for two consecutive days with 1 µM of TAT-Cre
Recombinase (SCR508, Merck Millipore) and 100 µM of Chloroquine (C6628,
Sigma) for 5 h; control cells were treated with 100 µM of Chloroquine only.
Fig. 5 Combined loss of Vhl and Pbrm1 is sufﬁcient to initiate renal carcinogenesis. a Top: schematic of crossings, tamoxifen (TAM) administration and
resulting cohorts. Bottom: Kaplan–Meier renal cancer-free survival of control and mutant mice. b Representative Haematoxylin and Eosin (H&E) and CA9
immunohistochemistry (IHC) images of serial renal sections from a Vhl−/−;Pbrm1−/− mouse. Scale bars, 100 μm. c Representative H&E sections of renal
neoplasias from Vhl−/−;Pbrm1−/− mice demonstrating cytoplasmic clearing (middle panels) and prominent thin-walled vasculature (right panel). Scale bar
in left panel, 1 mm. Other scale bars, 50 μm. d Images of serial sections of a representative renal tumour from a Vhl−/−;Pbrm1−/− mouse stained with H&E
or following immunohistochemical analyses with the indicated antibodies. Scale bars, 50 μm. e Schematic interpretation of the effects of VHL loss alone or
in combination with PBRM1 and their contributions to renal transformation
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Treatment was repeated at day 15 after recombination to ensure cultures remained
fully recombined. Recombination was conﬁrmed by PCR and immunoblotting.
Data were obtained from at least three independent experiments using primary
MEFs derived from a minimum of three different embryos and two separate pri-
mary cultures. For proliferation assays, cells were seeded in 12-well plates at 40,000
cells/ml in triplicate wells and counted after 4 days, before re-seeding at the same
density for the next passage. Cumulative population doubling was calculated as log
(Nf/Ni)/log2, where Ni and Nf correspond to number of cells plated and ﬁnal
counts/passage, respectively.
All cells tested negative for mycoplasma contamination.
Immunoblotting. MEFs were lysed in RIPA buffer with protease and phosphatase
inhibitors and lysates were processed using standard methods. We used the fol-
lowing primary antibodies: VHL (sc-5575, 1:250; Santa Cruz), PBRM1 (A301-
590A, 1:1000; Bethyl Laboratories), alpha-Tubulin (T5168, 1:2000; Sigma), RAD51
(sc-8349, 1:100; Santa Cruz), RPA32 (A300-244A, 1:500; Bethyl Laboratories),
pATM (ab36810, 1:1000; Abcam), ATM (ab85213, 1:1000; Abcam), pDNA-PKc
(ab18192, 1:1000; Abcam), DNA-PKc (ab70250, 1:1000; Abcam), pCHK1 (#2348 S,
1:500; Cell Signalling), CHK1 (#2360, 1:1000; Cell Signalling), H3K9me3 (ab8898,
1:1000; Abcam), H3K27me3 (ab6002, 1:1000; Abcam), H3K9me2 (ab8898, 1:1000;
Abcam), H4K20me3 (ab9053, 1:1000; Abcam), HP1a (ab77256, 1:1000, Abcam),
KAP1 (ab10484, 1:1000; Abcam) and H3 (4499, 1:2000; Cell Signalling). Secondary
antibodies were conjugated to IRDye 680 or 800 (Li-Cor). Fluorescent signals were
imaged using the Odyssey Infrared Imaging System (Li-Cor). Western blot band
quantiﬁcations were performed with Fiji58. Uncropped scans of presented blots are
shown in Supplementary Fig. 7.
Hypersensitivity assays. MEFs were seeded at 40,000 cells/ml on Ibidi 8-well
µSlides (IB-80826, Ibidi) and allowed to attach for 48 h before treatment. All cells
were treated with either mitomycin C (MMC) or aphidicolin (APH) at day 6 post
recombination. For MMC assays cells were treated with 2 µM of MMC (Sigma) for
2 h before replacing with either fresh media or media containing 200 nM of CDKi
(CDK1/2 Inhibitor III, 217714, Merck Chemicals) as speciﬁed. Alternatively, cells
were treated with 75 nM of Chaetocin for 24 h before adding 2 µM of MMC for 2 h.
After treatment, fresh media containing 75 nM of Chaetocin was added for a
further 24 h. For APH assays, aphidicolin (A4487, Sigma) was added at 200 nM
with or without 200 nM of CDKi for 24 h. Alternatively, cells were treated with 75
nM of Chaetocin for 24 h before adding aphidicolin 200 nM to the media for a
further 24 h.
Immunocytochemistry. MEFs grown on Ibidi 8-well µSlides were washed with
PBS and ﬁxed in 4% paraformaldehyde for 15 min. For pATR and pCHK1
detection, cells were permeabilized by treating them with CSK buffer (20 mM Tris,
300 mM glucose, 100 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100) for 12 min at
room temperature followed by incubation with CSK-S buffer (10 mM Tris, 10 mM
NaCl, 3 mM MgCl2, 1% Tween, 0.5% SDS) for 12 min. For other antibodies, cells
were permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were then
blocked in 2.5% normal donkey serum (NDS) for 1 h and incubated with primary
antibody diluted in 1% NDS overnight at 4 °C in a humid box. Cells were incubated
with Alexa ﬂuor ﬂuorochrome (Thermo Fisher) secondary antibodies diluted in 1%
NDS for 30 min at room temperature before being incubated with Hoechst 33258
(1 μg/mL, Thermo Fisher) for 5 min. The wells were washed with PBS and covered
with a drop of Mounting media (Ibidi). We used the following primary antibodies:
γH2AX (9718, 1:1,000; Cell Signalling and ab26350, 1:500; Abcam), 53BP1 (IHC-
00001, 1:500; Bethyl Laboratories), pATR (#2853, 1:500; Cell Signalling), pCHK1
(#2348S, 1:50, Cell Signalling), H3K9me3 (ab8898, 1:1000; Abcam), H2AZ (ab4174,
1:100; Abcam), H3K27me3 (ab6002, 1:500; Abcam), H3K9me2 (ab8898, 1:200;
Abcam), H4K20me3 (ab9053, 1:100; Abcam), HP1a (ab77256, 1:200; Abcam) and
KAP1 (ab10484, 1:500; Abcam). Image stacks of whole cells were obtained by
confocal laser-scanning microscopy (Leica TCS SP5) and automatic counting of
foci and nuclei detection was performed by an appropriate macro in Fiji. Asso-
ciation of γH2AX with H3K9me3 foci was analysed using Imaris software (Bit-
plane). In all studies more than 100 cells were analysed per genotype for each
experiment.
β-galactosidase staining. Cells were seeded at a density of 80,000 cells/ml in 12-
well plate 2 days prior the staining for β-galactosidase. At day 20 after recombi-
nation cells were washed with PBS and β-galactosidase activity was assessed using
the β-galactosidase staining kit (9860, Cell signalling) following the manufacture’s
protocol. Images were taken with NIKON Eclipse TS100 microscope and processed
with Fiji software for analysis. More than 150 cells were evaluated per genotype for
each experiment.
DNA ﬁbre assays. Asynchronous MEFs were labelled as indicated with 50 µM
iododeoxyuridine (IdU, Sigma I7125) followed by 500 µM of chlorodeoxyuridine
(CldU, Sigma C6891). Aphidicolin (200 nM) was added with the second pulse of
CldU or immediately after labelling with IdU as indicated. Cells were collected and
resuspended in PBS at a density of 1 × 106 cells/mL. 2 µL of cell suspension was
spotted onto a Superfrost microscope slide (Thermo Fisher) and overlaid with 7 µL
of DNA lysis buffer (200 mM Tris-HCl, 50 mM EDTA, 0.5% SDS). After 10 min,
the slides were tilted by 15 degrees to allow lysates to slowly move down the slide.
The DNA spreads were air-dried for 4 h, ﬁxed in a 3:1 mixture of methanol/acetic
acid for 10 min at room temperature and air-dried overnight. The slides were then
treated with 2.5 N HCl for 60 min at 37 °C, washed in PBS and incubated in
blocking buffer (5% BSA/PBS) for 30 min at room temperature followed by
incubation with a mouse anti-BrdU antibody (to detect IdU) (347590, 1:50, BD
Biosciences) and a rat anti-BrdU antibody (to detect CldU) (ab6326, 1:200,
Abcam). After washing three times with PBS, the slides were incubated for 12 min
in stringency buffer (36 mM Tris-HCl, 0.5 mM NaCl and 0.5% Tween), rinsed
three times in PBS and incubated for 30 min with Alexa Fluor 488-conjugated anti-
rat and Alexa Fluor 555-conjugate anti-mouse, washed in PBS and mounted in
Mounting media (Ibidi). Fibre images were obtained in a Leica DMI 6000B
microscope using a 63x objective. In each assay >100 ﬁbres were measured and
each individual experiment was repeated at least two times.
Real-time PCR. Total RNA was isolated from MEFs using the RNeasy Mini kit
(Qiagen). Puriﬁed RNA was reverse transcribed using the SuperScript II Reverse
Transcriptase kit (Thermo Fisher). Rad51 and RPA32 levels were measured using
the TaqMan gene expression assays and a Quantstudio 6 Instrument (Applied
Biosystems). Real-time quantitative PCRs were carried out following the manu-
facture’s protocol using the following probes: Mm00488047_m1 (RPA2),
Mm00487905_m1 (Rad51), Mm00437762_m1 (B2M), Mm03024075_m1 (HPRT).
Relative sample quantiﬁcation was carried out by the comparative DDCt method
using B2M and HPRT as endogenous controls.
Viability assays. At day 4 after recombination MEFs were seeded at 20,000 cells/
ml in triplicate in 96-well plates and allowed to attach for 48 h before treatment.
Mitomycin C was added to cells for 2 h at the stated concentrations before medium
was replaced with fresh growth medium. Viability was analysed 6 days following
treatment using MTT assay (CGD1, Sigma) according to the manufacturer’s
protocol.
Histology and immunohistochemistry. At experimental end-points animals were
euthanized and tissues were ﬁxed in 4% paraformaldehyde in PBS overnight and
embedded in parafﬁn. To review histology, 4 µm sections were stained with hae-
matoxylin and eosin (H&E). Immunohistochemistry (IHC) and immuno-
ﬂuorescence (IF) were performed on 4 µm tissue sections using standard protocols.
Speciﬁcity of immunostaining was assessed by incubation in the absence of primary
or secondary antibody. We used the following primary antibodies: γH2AX (9718,
1:1000; Cell Signalling), H3K9me3 (ab8898, 1:500; Abcam), p21 (sc-471, 1:2000;
Santa Cruz), ki67 (NCL-ki67p, 1:1000; Novacastra), PBRM1 (A301-591A, 1:2000;
Bethyl Laboratories), CA9 (sc-25600, 1:200; Santa Cruz), aquaporin 2 (ab105171,
1:1000; Abcam), megalin (ab76969, 1:1000; Abcam) and Tamm–Horsfall protein
(THP; AF5175, 1:1000; R&D Systems). Secondary antibodies used were conjugated
to HRP (IHC) or Alexa ﬂuor ﬂuorochromes (IF). Fluorescent images were obtained
by confocal laser-scanning microscopy (Leica TCS SP5). All histology was inde-
pendently reviewed by a specialist renal pathologist.
For quantiﬁcation of γH2AX, p21 and ki67 expression, stained tissue sections
were scanned with the Aperio ScanScope (Aperio, Vista, CA) and images were
visualised and captured using the Aperio ImageScope program. Quantiﬁcation was
performed on a minimum of 15 ﬁelds (×20 magniﬁcation) from three
representative coronal kidney sections per animal. Images were processed using Fiji
software by calculating the percentage of DAB positive nuclei relative to total
number of nuclei within the ﬁeld (a minimum of 8000 cells were analysed per
animal).
For quantiﬁcation of H3K9me3, a minimum of 10 image stacks were obtained
from at least 2 coronal sections of kidney per animal by confocal laser-scanning
microscopy (Leica TCS SP5). Nuclei detection and foci counting was performed
automatically by an appropriate macro in FIJI. At least 6000 cells were analysed per
animal. For quantiﬁcation of γH2AX/CA9 co-immunostaining, a minimum of six
image stacks were obtained from at least two coronal sections of kidney per animal
by confocal laser-scanning microscopy (Leica TCS SP5). Staining was quantiﬁed
automatically by an appropriate macro in FIJI. At least 10,000 cells were analysed
per animal.
Quantitative PCR. Genomic DNA from macroscopically normal renal cortical
parenchyma was extracted using standard protocols. For quantitative PCR (qPCR)
of the Vhl deletion, SYBR Green PCR Master Mix (Applied Biosystems) was used
and ampliﬁcation and analysis was carried out on QuantStudio 6 (Thermo Fisher
Scientiﬁc). Primers forward 5′-CTGGTACCCACGAAAGTGTC-3′ and reverse 5′-
CTGACTTCCACTGATGCTTGTCACAG-3′ were used to detect the recombined
allele (Vhl−). Serial dilutions of fully recombined Vhl−/− MEF DNA were used to
construct a standard curve and to determine Vhl− allelic frequency.
Genotyping. Genotyping of MEFs and additional genotyping of mice was performed
by PCR using the following primers and conditions. Vhl allele recombination: for-
ward primer for ﬂoxed allele 5′-CCGGAGTAGGATAAGTCAGCTGAG-3′, forward
primer for recombined allele 5′-CTGGTACCCACGAAAGTGTC-3′, common
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reverse primer 5′-CTGACTTCCACTGATGCTTGTCACAG-3′ (400 bp product for
ﬂoxed allele, 200 bp product for WT and 250 bp product for recombined allele); 1
cycle of 10min 94 °C, 55 cycles of (50 sec 95 °C, 50 sec 58 °C, 60 sec 72 °C), 1 cycle of
5 min 72 °C16. Cre recombinase: forward primer 5′-GCACTGATTTCGAC-
CAGGTT-3′, reverse primer 5′-GCTAACCAGCGTTTTCGTTC-3′ (200 bp pro-
duct); Pbrm1 allele recombination: forward primer 5′-
GCAGGAGAGTTATATAAGCCAATAAGCTG-3′, reverse primer 5′-TGA-
CACCAAAGAGTTCTCCAGGATCA-3′ (1266 bp product for ﬂoxed allele, 1119 bp
product for WT and 423 bp product for recombined allele); 1 cycle of 1 min 95 °C, 30
cycles of (15 s 95 °C, 30 s 58 °C, 1 min 68 °C), 1 cycle of 5 min 68 °C.
Statistical analysis. Data were visualised and statistical analyses performed using
Prism 7.0 software (Graph Pad). P< 0.05 was considered statistically signiﬁcant.
For cases where experimental groups showed comparable variance the following
statistical tests were applied. P-values for unpaired comparisons between two
groups were calculated by two-tailed Student’s t-test, whilst P-values for paired
comparisons were calculated by two-tailed paired t-test. One-way analysis of var-
iance (ANOVA) was used for analysis between three or more groups, followed by
appropriate multiple comparison correction. Ordinary two-way ANOVA was used
for analysis that involved two variables, followed by appropriate multiple com-
parison correction. For experiments showing non-comparable variance between
groups the Kruskall–Wallis test was applied followed by Dunn’s correction for
multiple comparisons. *P< 0.05; **P< 0.01; ***P< 0.001; ***P< 0.0001. Error
bars, mean± s.d. or s.e.m., as indicated.
Data availability. The data that support the ﬁndings of this study are available
within the Article and Supplementary Files, or available from the authors upon
request.
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